Inbiomotion SL today announced the publication of the results of the Phase 3 AZURE prospective/retrospective analysis using its proprietary single gene based MAFTest® in the November issue of Lancet Oncology
Inbiomotion: Personalized adjuvant treatment of early stage breast cancer
Inbiomotion is focused on the development and commercialization of a biomarker that predicts metastasis to improve patients' quality of life by personalizing the adjuvant treatment of early stage breast cancer. Founded in 2010 by Dr. Roger Gomis, it is a spin-off of IRB Barcelona and ICREA research institutions.
Inbiomotion's unique diagnostic assay is based on a highly selective single gene biomarker. Data generated thus far suggests such biomarker can identify early stage breast cancer patients that will benefit from bisphosphonate adjuvant treatment improving their overall and invasive disease free survival. It can further predict at an early stage a patient's risk of metastases relapse from primary tumors. The selectivity of the lead biomarker has the potential to advance the clinical standard of care using personalized medicine.